Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study

Clicks: 446
ID: 118301
1970
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #3 of 48 articles by views in Diagnostic microbiology and infectious disease

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The in vitro activity of gemifloxacin, a new fluoroquinolone, was compared to three marketed fluoroquinolones; ciprofloxacin, levofloxacin and ofloxacin against over 4,000 recent clinical isolates covering 29 species isolated in the United States and Canada between 1997-1999. Based on MIC(90)s, gemi …
Reference Key
dj1970diagnosticcomparative Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hoban DJ;Bouchillon SK;Johnson JL;Zhanel GG;Butler DL;Miller LA;Poupard JA; ;;
Journal Diagnostic microbiology and infectious disease
Year 1970
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/11448564
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't united states / epidemiology Comparative Study microbial sensitivity tests gram-negative bacterial infections / epidemiology gram-negative bacterial infections / microbiology anti-infective agents / pharmacology* fluoroquinolones* gram-negative bacteria / drug effects* population surveillance* canada / epidemiology pmid:11448564 doi:10.1016/s0732-8893(01)00241-3 d j hoban s k bouchillon gemifloxacin surveillance study research group gemifloxacin gram-positive bacteria / drug effects* gram-positive bacterial infections / epidemiology gram-positive bacterial infections / microbiology naphthyridines / pharmacology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.